| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 30,250 | 56,590 | 46,740 | 38,030 | 0 |
| Sales Growth | -46.55% | +21.07% | +22.90% | unch | unch |
| Net Income | -358,730 | -72,810 | -114,330 | -23,360 | 780 |
| Net Income Growth | -392.69% | +36.32% | -389.43% | -3,094.87% | +7,900.78% |
Scilex Holding Company WT (SCLXW)
Scilex Holding Company WT (SCLXW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Scilex Holding Company is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain. Scilex Holding Company, formerly known as Vickers Vantage Corp. I, is based in PALO ALTO, Calif.
Fiscal Year End Date: 12/31